Cargando…

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice

BACKGROUND: Farnesoid X receptor (FXR), a bile acid–activated nuclear receptor, is a potent regulator of glucose and lipid metabolism as well as of bile acid metabolism. Previous studies have demonstrated that FXR deficiency is associated with metabolic derangements, including atherosclerosis and no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yenna, Kim, Bo-Rahm, Kang, Geun-Hyung, Lee, Gwan Jae, Park, Young Joo, Kim, Haeryoung, Jang, Hak Chul, Choi, Sung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743579/ https://www.ncbi.nlm.nih.gov/pubmed/34986301 http://dx.doi.org/10.3803/EnM.2021.1100

Ejemplares similares

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

AMPK-Dependent Metabolic Regulation by PPAR Agonists
por: Lee, Woo Hyung, et al.
Publicado: (2010)

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
por: Han, Yoon-Mi, et al.
Publicado: (2020)

Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice
por: Lee, Yong-Jik, et al.
Publicado: (2017)

FXR an emerging therapeutic target for the treatment of atherosclerosis
por: Mencarelli, Andrea, et al.
Publicado: (2010)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
por: Jin, Lihua, et al.
Publicado: (2015)

Corrigendum to “Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice”
por: Lee, Yong-Jik, et al.
Publicado: (2019)

Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR
por: Lee, Jae Man
Publicado: (2016)

Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling
por: Pan, Linyu, et al.
Publicado: (2023)

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease
por: Mazzini, Guilherme S., et al.
Publicado: (2018)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging
por: Kim, Seong Min, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis
por: Sinn, Dong Hyun, et al.
Publicado: (2016)

Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis Beyond Metabolic Disorders in Non-Diabetic Patients
por: Kang, Ji Hoon, et al.
Publicado: (2012)

LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR‐92a/FXR1 axis
por: Yang, Liu, et al.
Publicado: (2020)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

Fatty liver diseases, bile acids, and FXR
por: Zhu, Yan, et al.
Publicado: (2016)

Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis
por: Kang, Min Kyoung, et al.
Publicado: (2015)

Association and Prediction of Subclinical Atherosclerosis by Nonalcoholic Fatty Liver Disease in Asymptomatic Patients
por: Bae, Ye Seul, et al.
Publicado: (2020)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
por: Lee, Han Ah, et al.
Publicado: (2023)

Novel predictors of early atherosclerosis in nonalcoholic fatty liver disease
por: Abdulaziz, Badawy Abdulkhalik, et al.
Publicado: (2023)

Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2023)

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
por: Kang, Seong Hee, et al.
Publicado: (2021)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease
por: Kim, Min Chul, et al.
Publicado: (2020)

High ApoB/ApoA-I Ratio Predicts Post-Stroke Cognitive Impairment in Acute Ischemic Stroke Patients with Large Artery Atherosclerosis
por: Lee, Minwoo, et al.
Publicado: (2023)

Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases
por: Kim, Han-Na, et al.
Publicado: (2019)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis
por: Xu, Xin, et al.
Publicado: (2015)

Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis
por: Rasool, Abid, et al.
Publicado: (2017)

Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease
por: Taylan, Gökay, et al.
Publicado: (2022)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_djse7jmqefmsmbna3qrbtjkv6f